Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Argenx Se ADR (ARGX)

Argenx Se ADR (ARGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Argenx Se ADR LAARDERHOOGTWEG 25 AMSTERDAM P7 1101EB NLD

www.argenx.com Employees: 1,599 P: 31-10-703-8441

Sector:

Medical

Description:

argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands.

Key Statistics

Overview:

Market Capitalization, $K 52,430,984
Enterprise Value, $K 50,931,044
Shares Outstanding, K 61,883
Float, K 60,379
% Float 97.57%
Short Interest, K 1,816
Short Float 2.93%
Days to Cover 4.82
Short Volume Ratio 0.46
% of Insider Shareholders 2.43%
% of Institutional Shareholders 60.32%

Financials:

Annual Sales, $ 2,252 M
Annual Net Income, $ 833,040 K
Last Quarter Sales, $ 1,151 M
Last Quarter Net Income, $ 344,260 K
EBIT, $ 789,230 K
EBITDA, $ 806,760 K

Growth:

1-Year Return 32.36%
3-Year Return 131.16%
5-Year Return 156.22%
5-Year Revenue Growth 2,334.90%
5-Year Earnings Growth 154.33%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 5.18 on 10/30/25
Next Earnings Date 02/26/26 [BMO]
Earnings Per Share ttm 13.08
EPS Growth vs. Prev Qtr 38.50%
EPS Growth vs. Prev Year 272.66%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

ARGX Ratios

Ratio
Price/Earnings ttm 64.63
Price/Earnings forward 29.89
Price/Earnings to Growth 0.73
Return-on-Equity % 29.78%
Return-on-Assets % 25.81%
Profit Margin % 36.99%
Debt/Equity 0.00
Price/Sales 15.47
Price/Cash Flow 283.98
Price/Book 8.47
Book Value/Share 0.00
Interest Coverage 35.63
60-Month Beta 0.37
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar